Sentence examples for issued in ad from inspiring English sources

This "reformed coinage" was of gold (first issued in ad 698 699), silver (first issued in 696 697), and copper.

The art of coinage was borrowed from China by Japan, whose first bronze coins were issued in ad 708.

For example, in 2006, the National Institute for Health and Care Excellence in England first published guidance on the use of medications and treatments for AD; this was amended in 2007 and 2009, and new updated guidance that recommended extending the use of drug treatment in AD was issued in 2011.

"An edict was issued in the first century AD halting the planting of vineyards because people were not growing wheat any more," said Indelicato. "The Romans took the concept of getting together for a drink from the Greeks after they conquered the Greek-controlled Italian city of Taranto in the third century BC. "They drank at festivals to mark the pending harvest, after the harvest.

The National Institute for Health and Clinical Excellence (NICE) guidance on the use of these drugs in the treatment of AD, first issued in 2001, has always recommended that treatment should be initiated by a specialist and prescribing taken over by GPs as part of a shared care protocol.

One of the key issues in ad hoc and sensor network is the energy consumption.

Most of security issues in ad hoc networks are not entirely employed nor considered in vehicular communication.

In [29], the authors systematically studied the connectivity issue in ad hoc networks and proposed several approximation algorithms for computing k-connectivity topology using minimal transmission power.

Some of the most important issues in ad hoc networks are finding and maintaining routes, as host mobility can cause topology changes; efficient transport and reliable data delivery; and network security.

The kinetics of amyloid plaque formation and growth as one of the characteristic hallmarks of Alzheimer's disease (AD) are fundamental issues in AD research.

The lack of correlation between markers of target engagement and clinical outcome measures is still an unsolved issue in AD trials, which mirrors the knowledge gap of the disease pathogenesis.